Cargando…
Gut microbiota composition during a 12-week intervention with delayed-release dimethyl fumarate in multiple sclerosis – a pilot trial
INTRODUCTION: Patients with multiple sclerosis may have a distinct gut microbiota profile. Delayed-release dimethyl fumarate is an orally administered drug for relapsing–remitting multiple sclerosis, which has been associated with gastrointestinal side-effects in some patients. OBJECTIVES: The purpo...
Autores principales: | Storm-Larsen, C, Myhr, K-M, Farbu, E, Midgard, R, Nyquist, K, Broch, L, Berg-Hansen, P, Buness, A, Holm, K, Ueland, T, Fallang, L-E, Burum-Auensen, E, Hov, JR, Holmøy, T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859687/ https://www.ncbi.nlm.nih.gov/pubmed/31798939 http://dx.doi.org/10.1177/2055217319888767 |
Ejemplares similares
-
Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis
por: Norborg, Hilde, et al.
Publicado: (2021) -
Dimethyl fumarate for ischemic stroke
por: Kunze, Reiner
Publicado: (2017) -
Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice
por: Yao, Yang, et al.
Publicado: (2016) -
Effects of dimethyl fumarate on neuroprotection and immunomodulation
por: Albrecht, Philipp, et al.
Publicado: (2012) -
Dimethyl fumarate mitigates optic neuritis
por: Zyla, Katarzyna, et al.
Publicado: (2019)